论文部分内容阅读
本文对21项临床和血液学预后参数进行评价,作多回归分析。72例供研究病人是按FAB标准诊断的骨髓增生异常综合征患者,未接受过化疗和放疗,诊断后64例接受大剂量睾丸酮肌注治疗,随访6-198月。21项预后参数与存活期的关系用分段多回归分析进行研究。结果中数存活期35.1月,54.9%、38.8%和29.4%患者分别存活2、5、10年,大部分患者仍存活,11例(15%)死于白血病。21项参数中Hb、骨髓原始细胞比例、骨髓细胞增生度(髂脊骨髓活检确定)和年龄对预测存活期有意义。E/M(原红细胞%/原粒细胞%)在平均E/M(0.53)以上和以下患者间存活期差异不显著,但大部分存活期小于20月患者(26/33)E/M很低或很高,其中9例(34%)(E/M<0.3.9例中的6例,E/M>2.0,7例中3例)
In this paper, 21 clinical and hematological prognostic parameters for multiple regression analysis. Seventy-two patients with myelodysplastic syndrome diagnosed according to FAB criteria were given chemotherapy and radiotherapy. Sixty-four patients were treated with high-dose testosterone intramuscular injection after 6 to 198 months of follow-up. The relationship between 21 prognostic parameters and survival was studied by piecewise multiple regression analysis. Results In median survival 35.1 months, 54.9%, 38.8% and 29.4% of patients survived for 2.5 years and 10 years, respectively. Most of the patients survived and 11 (15%) died of leukemia. The 21 parameters of Hb, bone marrow blast cell ratio, bone marrow cell proliferation (iliac spine bone marrow biopsy determination) and age of predicting survival meaningful. There was no significant difference in E / M (% of original red blood cells /% of neutrophils) survival between patients with and above average E / M (0.53), but most patients with survival of less than 20 months (26/33) Low or high, of which 9 (34%) (E / M <0.3.9, 6, E / M> 2.0, and 7 of 3)